GlassScriptPhysician profile
Martin C Degraw
NPI 1851345920
$6,868.84
in general payments reported to CMS, 2019-2025
52 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,929 · 2020: $1,340 · 2021: $1,887 · 2022: $467 · 2023: $625 · 2024: $479 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,151.00 | 2019-2024 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $974.59 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $727.81 | 2019-2024 | Spravato |
| Glaxosmithkline, LLC. | $469.99 | 2019-2024 | Arexvy, Shingrix |
| Abbott Laboratories | $341.80 | 2021-2025 | Freestyle Libre 2 |
| Eisai INC. | $284.49 | 2020-2021 | |
| Abbvie INC. | $228.02 | 2019-2023 | Vraylar |
| Novo Nordisk INC | $218.85 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $214.53 | 2020-2021 | |
| Daiichi Sankyo INC. | $199.85 | 2020-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.35 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.20 | 2021 | |
| Grifols USA, LLC | $129.42 | 2019-2023 | Prolastin-C Liquid |
| Phathom Pharmaceuticals, INC. | $120.41 | 2024 | Voquezna |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Degraw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.